Healthcare - Page 1 | TalkMarkets
All Posts > Content under Healthcare
1 to 16 of 4647 Posts
1 2 3 ... 291
Why The Dividend Aristocrats Are Good Investments To Generate Long-Term Wealth
Article By: SureDividend
Saturday, December 16, 2017 4:15 PM EST
For most, the destination of investing is financial independence. The stock market is an excellent vehicle to accomplish this. More specifically, dividend growth stocks have generated strong returns over the past several decades.
In this article: JNJ, KO, PG
Read
Ask Slim Market Week - Friday, Dec. 15
Video By: Steve Miller
Friday, December 15, 2017 9:40 PM EST
A look back at what happened in the financial market in the past week and a look forward to what might happen next week.
In this video: ANF, SPX, AAPL, NDX, BABA, TSLA, DDD, TEVA, UAA, FCX, OIL, UNG, NBR, CSX, NE, RIG, UUP, FXE
Watch
Credit Suisse Takes Teva Rating To Neutral In Third Upgrade Of Day
Article By: The Fly
Friday, December 15, 2017 1:12 PM EST
Credit Suisse analyst Vamil Divan upgraded earlier today Teva Pharmaceutical to Neutral from Underperform and raised his price target for the shares to $20.
In this article: TEVA
Read
Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
Article By: Arpita Dutt
Friday, December 15, 2017 11:07 AM EST
Key announcements this week were Teva Pharmaceutical Industries Ltd.’s restructuring plan and Eli Lilly and Company’s 2018 outlook.
In this article: TEVA, LLY, RHHBY, BMY, MRK, SNY, GSK
Read
Global Blood Therapeutics Prices A $100.0 Million Common Stock Public Offering
Article By: NASDAQ GlobeNewswire
Friday, December 15, 2017 9:49 AM EST
Global Blood Therapeutics, Inc. today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $100.0 million.
In this article: GBT
Read
Will $5 Billion In Near-Term Principal Payments Sink Teva?
Article By: Shock Exchange
Friday, December 15, 2017 6:00 AM EST
Teva announced it was laying off 25% of its workforce in order to cut costs. It has $5B in principal payments due in 2018 and $19B due over the next three years. Restructuring these debt payments could create headwinds for the stock.
In this article: TEVA Also: MYL
Read
4 Growth Stocks To Pick From A Choppy MedTech Market
Article By: Zacks Investment Research
Thursday, December 14, 2017 6:39 PM EST
The U.S. investment space has been fraught with uncertainties of late. The healthcare industry, in particular, has been facing multiple issues, with the Obamacare-repeal saga dominating the headlines.
In this article: CHE, BABY, CGNT, LIVN
Read
Valeant Slips After JPMorgan Says Sell On Stretched Valuation, High Expectations
Article By: The Fly
Thursday, December 14, 2017 4:16 PM EST
Shares of Valeant Pharmaceuticals are sliding after JPMorgan analyst Chris Schott downgraded the stock to Underweight.
In this article: VRX
Read
Hot Options Report For End Of Day - Wednesday, December 13
Article By: The Options Insider
Wednesday, December 13, 2017 4:25 PM EST
Top Tickers For End Of Day December 13th: T, TWX, MRK, GILD, BX, M, MRO and AAPL.
In this article: T, TWX, MRK, GILD, BX, M, MRO, AAPL
Read
Teva In Focus Ahead Of Restructuring As Former Interim CEO Exits Board
Article By: The Fly
Wednesday, December 13, 2017 1:41 PM EST
Shares of Teva Pharmaceutical are in focus following reports that the company will unveil a new restructuring plan that will include layoffs as part of the company's plans to reduce debt and improve its performance.
In this article: TEVA Also: MYL, AGN
Read
Acer Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Wednesday, December 13, 2017 12:30 AM EST
The underwritten public offering of 916,667 shares of its common stock is set at a public offering price of $12.00 per share.
In this article: ACER
Read
Biotech Digest – XENT Gets FDA Approval, AGN Announces Acquisition, IONS Licenses Product
Article By: KKD Healthcare Analytics
Tuesday, December 12, 2017 10:26 AM EST
Intersect ENT Inc. reported the FDA approval for its SINUVA implant, designed to be used for treating recurrent nasal polyps in patients who have had previous ethmoid sinus surgery.
In this article: AGN, MRK, SNY, REGN, RPRX, XENT, IONS, TYHT
Read
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Article By: Arpita Dutt
Monday, December 11, 2017 7:45 PM EST
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.
In this article: JUNO, BLUE, INCY Also: SNY, AMGN, JNJ, GILD
Read
E Ford Model T And Personalized Medicine
Article By: Ketan Desai
Monday, December 11, 2017 10:35 AM EST
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
In this article: JUNO, KITE, EDIT
Read
3 Canadian Cannabis Trends To Watch Entering The New Year
Article By: Technical420
Monday, December 11, 2017 8:32 AM EST
The Canadian cannabis sector ended on a high note last week and many investors are monitoring how the sector closes out the year.
In this article: APHQF, TWMJF, ACBFF, PRMCF, CMMDF, MRRCF
Read
Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Wednesday, December 6, 2017 12:25 PM EST
Editas Medicine, Inc., a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock.
In this article: EDIT
Read
1 to 16 of 4647 Posts
1 2 3 ... 291